Evaluation of an African swine fever (ASF) vaccine strategy incorporating priming with an alphavirus-expressed antigen followed by boosting with attenuated ASF virus

Arch Virol. 2019 Feb;164(2):359-370. doi: 10.1007/s00705-018-4071-8. Epub 2018 Oct 26.

Abstract

In this study, an alphavirus vector platform was used to deliver replicon particles (RPs) expressing African swine fever virus (ASFV) antigens to swine. Alphavirus RPs expressing ASFV p30 (RP-30), p54 (RP-54) or pHA-72 (RP-sHA-p72) antigens were constructed and tested for expression in Vero cells and for immunogenicity in pigs. RP-30 showed the highest expression in Vero cells and was the most immunogenic in pigs, followed by RP-54 and RP-sHA-p72. Pigs primed with two doses of the RP-30 construct were then boosted with a naturally attenuated ASFV isolate, OURT88/3. Mapping of p30 identified an immunodominant region within the amino acid residues 111-130. However, the principal effect of the prime-boost was enhanced recognition of an epitope covered by the peptide sequence 61-110. The results suggest that a strategy incorporating priming with a vector-expressed antigen followed by boosting with an attenuated live virus may broaden the recognition of ASFV epitopes.

MeSH terms

  • African Swine Fever / immunology*
  • African Swine Fever / prevention & control
  • African Swine Fever / virology
  • African Swine Fever Virus / genetics
  • African Swine Fever Virus / immunology*
  • Alphavirus / genetics
  • Alphavirus / metabolism
  • Animals
  • Antibodies, Viral / immunology
  • Antigens, Viral / administration & dosage
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology*
  • Chlorocebus aethiops
  • Drug Evaluation, Preclinical
  • Gene Expression
  • Immunization, Secondary
  • Immunodominant Epitopes / administration & dosage
  • Immunodominant Epitopes / genetics
  • Immunodominant Epitopes / immunology
  • Swine
  • Vero Cells
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Immunodominant Epitopes
  • Viral Vaccines